Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

AI app aims to help frontline workers diagnose neglected skin diseases

NCT ID NCT07506967

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a mobile app using artificial intelligence can help frontline health workers in sub-Saharan Africa better diagnose skin-related neglected tropical diseases, like leprosy and scabies. Researchers will collect images from dermatologists to train the AI, then have health workers use the app to see if their diagnostic accuracy improves. The goal is to boost early detection and care in underserved communities.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
AI-powered mobile app for diagnosing skin diseases
What this could lead to
If successful, this AI tool could help frontline health workers in remote areas detect skin diseases earlier, improving treatment and disease tracking.
What could go wrong
This is an early-stage study testing the app's feasibility. The AI may not improve diagnosis enough, and results may not apply to all regions or diseases.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 2,420 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

May 2026

An estimate. Start dates often move.

Expected to finish

May 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

0 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

1. Frontline Health Workers (FHWs) Age Group * Age Range: 18 years and above o Justification: FHWs must be adults, legally eligible to provide healthcare services and consent to participate in the study Sex Distribution * Male and Female FHWs o Justification: Both male and female FHWs will be included to reflect the actual workforce distribution and to ensure generalizability of the results across genders. Inclusion criteria for FHWs: 1. Professional Role: o Must be working as a FHW at one of the selected health centers at the time of the validation study. ▪ Justification: The study aims to assess the diagnostic performance of those directly involved in primary patient care in the targeted settings. 2. Willingness to Participate: o Willing to provide written informed consent to participate in the study. ▪ Justification: Ethical standards require voluntary participation with informed consent. 3. Smartphone Usage: o Willing and able to use a smartphone during the study. ▪ Justification: The SkincAIr app is smartphone-based; therefore, FHWs must be willing to use and have access to such devices. 4. No Specialized Dermatology Training: * FHWs without specialised training in dermatology or extensive experience in skin disease diagnosis. * Justification: The study aims to evaluate the app's effectiveness among generalist healthcare workers who would benefit most from diagnostic support tools. Exclusion criteria for FHWs: 1\. Prior Specialised Training in dermatology: o FHWs with formal education or extensive experience in dermatology. * Justification: Including specialists could skew results, as their baseline diagnostic accuracy may already be high, reducing the observable impact of the app. 2\. Refusal or Inability to Consent: * FHWs unwilling or unable to provide written informed consent. * Justification: Ethical compliance requires informed consent for participation. 3. Inability to Use the App: o FHWs unable to use a smartphone due to technical limitations, physical impairments, or lack of familiarity with the technology. * Justification: Effective use of the app is essential for the intervention; inability to use it would prevent meaningful participation. 2. Patients with Skin complaints Size ● Total Patients: \~750 patients Age Group ● All Age Groups: o Justification: Skin-NTDs affect individuals of all ages; including all age groups enhances the generalizability of the findings and assesses the app's effectiveness across the lifespan. Sex Distribution * Male and Female Patients * Justification: Both sexes are included to capture the full spectrum of the disease burden and ensure the app's diagnostic accuracy is effective regardless of sex. Inclusion Criteria for Patients with Skin complaints: 1\. Presenting with Skin Complaints: o Patients presenting to participating health centres with symptoms suggestive of skin-NTDs (e.g., visible skin lesions, nodules, ulcers) but have not been diagnosed by a specialist for that specific skin condition. * Justification: The study aims to evaluate the app's effectiveness in real-world conditions, including all patients with potential skin-NTDs 2. Willingness to Participate: o Patients (or guardians, in the case of minors) willing to provide written informed consent for participation. * Justification: Ethical standards require informed consent from patients or their legal guardians. 3\. Ability to Comply with Study Procedures: o Patients are able to follow study instructions and attend necessary follow-up appointments. * Justification: Ensures complete data collection and accurate assessment of outcomes. 4\. Patients with Co-morbid conditions: * Justification: Immunosuppression that occurs in some comorbid conditions e.g. HIV/AIDS or severe malnutrition can reveal the Skin disease and can affect both the clinical progression and even severity of the Skin NTD. This also includes patients with multiple skin-NTDs. Exclusion Criteria for Patients with Skin complaints: 1. Refusal or Inability to Consent: o Patients (or guardians) unwilling or unable to provide written informed consent. ▪ Justification: Ethical compliance requires informed consent for participation. 2. Non-Skin-Related Complaints: o Patients presenting with complaints unrelated to skin conditions. ▪ Justification: The study focuses on skin-NTDs; including unrelated cases would not contribute to the study objectives. 3. Previous Participation in the Study: o Patients who have already participated in the study. ▪ Justification: To avoid duplicate data and potential bias in outcomes. Additional Considerations: Diversity and Representation ● Geographical Diversity: o Including health centres from different regions within each country ensures that the findings are representative of various settings (urban, peri-urban, rural). ● Cultural and Socioeconomic Factors: o The study acknowledges that cultural beliefs and socioeconomic status may influence healthcare-seeking behaviour and disease presentation. By including a diverse patient population, the study aims to capture these variations. Ethical Justification ● Inclusivity: * Including all age groups and both sexes aligns with ethical principles of justice and fairness, ensuring that the benefits of the research are accessible to all segments of the population. * Vulnerable Populations: * While including minors and potentially vulnerable adults, the study will implement additional safeguards to protect their rights and well-being, following ethical guidelines and obtaining consent from guardians when necessary.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Buruli ulcer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    5 sites in 5 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Armauer Hansen Research Institute (AHRI)

    Addis Ababa, Addis Ababa, Ethiopia

  • Centre Hospitalier de l'Ordre de Malte (CHOM)

    Dakar, Dakar, Senegal

  • Kenya Medical Research Institute (KEMRI)

    Kisumu, Nyanza, Kenya

  • Leprosy and Tuberculosis Relief Initiative Nigeria (LTR)

    Jos, Plateau State, Nigeria

  • Université Catholique de Bukavu (UCB)

    Bukavu, South Kivu, Democratic Republic of the Congo

More trials for these conditions

Other studies related to the condition(s) this trial covers.